A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-142 in Healthy Adult Subjects and Single Doses of ABBV-142 in Healthy Adult Asian Subjects
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs ABBV 142 (Primary) ; ABBV 142 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 24 Jan 2025 Status changed from not yet recruiting to recruiting.
- 22 Jan 2025 New trial record